NCT04578600 - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

December 12, 2023

Study Completion Date

February 21, 2025

Conditions

Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Mucosa-Associated Lymphoid Tissue LymphomaRecurrent Follicular LymphomaRecurrent Hairy Cell LeukemiaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Mucosa-Associated Lymphoid Tissue LymphomaRefractory Follicular LymphomaRefractory Hairy Cell LeukemiaRefractory Lymphoplasmacytic LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Small Lymphocytic Lymphoma

Interventions

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Oral Azacitidine

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento